Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Files Registration Statement to Raise Additional Funds

NEW YORK, July 30 – Exelixis of South San Francisco, Calif., has filed a shelf registration with the Securities and Exchange Commission to offer up to $150 million in common stock.

The company said it was considering raising additional funds to help support the development of cancer drug rebeccamycin, which it recently acquired from Bristol-Myers Squibb, as well as for other drug discovery and corporate activities.

Exelixis recently announced initiatives to expand its activities in two major disease areas: metabolic disorders and cancer. Last week the company said it was expanding its internal drug discovery efforts into metabolic diseases, including cardiovascular disease, diabetes, and obesity.

That announcement came one week after Exelixis announced a major push into oncology via the formation of a partnership with Bristol-Myers Squibb to identify genes associated with tumor suppression using its invertebrate and vertebrate gene knockout models.

Companies generally file shelf registrations when market conditions are poor. By filing the statement, a company lays the groundwork for issuing shares so that it can act quickly to raise fresh funds as soon as market conditions become more favorable.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.